USSTOCK.TODAY
Pre-Market
Log in Sign up
No quote
Stale quote No price data has been collected for the last 5 trading days. We are checking whether trading has been halted or the listing has been delisted. The description below is for reference only.
Company overview

What Does EDAP TMS ($EDAP) Do? Stock Outlook, Earnings, Market Cap, Related Stocks and Headquarters Explained

Updated October 9, 2026 · First published April 17, 2026

EDAP TMS (EDAP) is a robotic focused ultrasound therapy device company headquartered in Lyon, France. It has moved its lithotripsy and distribution businesses into discontinued operations and restructured around a single pillar, Focal One. Growth in its installed base of devices is the key variable for revenue and the stock outlook.

Briefs · earnings · signals, first Subscribe

🏢 What Kind of Company Is EDAP TMS?

EDAP TMS (EDAP) is a medical device company specializing in therapeutic ultrasound, founded in 1979 and headquartered in Lyon, France. It develops and manufactures minimally invasive treatment devices for urology, and it focuses on expanding its patented robotic focused ultrasound treatment platform in clinical settings. Recently, it changed its identity with a new corporate name, Focalyx.

Its core business is Focal One, a robotic high-intensity focused ultrasound device. It is a focal therapy approach that targets only the diseased areas of prostate tissue, and revenue comes from both device sales and per-procedure consumables and services. Extracorporeal shock wave lithotripsy and the distribution of third-party products have been classified as discontinued operations.

💰 How Does EDAP TMS Make Money?

Business SegmentRevenue ShareDescription
Focused ultrasound (Focal One)Main and only continuing businessSales of robotic high-intensity focused ultrasound devices, procedure consumables, maintenance services
Extracorporeal shock wave lithotripsyDiscontinued operationsUrinary stone treatment device business, reclassified as discontinued operations
DistributionDiscontinued operationsDistribution of third-party medical devices such as lasers, reclassified as discontinued operations

In the past, revenue was split across three segments: focused ultrasound, lithotripsy devices, and distribution of third-party products. The company has since reclassified lithotripsy and distribution as discontinued operations. Going forward, continuing revenue will consist of Focal One device sales and consumables and service revenue generated from the installed base. As the number of devices sold and the installed base keep growing, the share of recurring revenue is increasing. However, with the business narrowed to a single pillar, the benefits of revenue diversification shrink. Profitability remains in loss territory, so expanding sales is the key.

📐 EDAP TMS Market Cap and Company Size

Its market capitalization is $161.9M, and its workforce is 289 people.

By market cap, it is a micro-cap medical device company. In prostate treatment devices it is far smaller than the large medical device groups, and it stands as a specialist focused on the niche area of focal therapy. As it is in a growth-investment stage, it has no capital return policies such as dividends or share buybacks, and it raises funds through capital increases when needed.

📈 EDAP TMS Outlook and Stock Price Trend

1-Year Price Performance
Analyst Consensus
2.3
Sell Hold Strong Buy
Target Price $6 +35.0% Current $4
52-Week Price Range
$4
Low $1 High $5
vs. low +257.02% vs. high -14.46%

In the short term, the change in earnings structure from the business restructuring and the wind-down of discontinued operations are the main variables in earnings releases. Mid- to long-term growth drivers are the expansion of the Focal One installed base, improvement in the US reimbursement environment, and the accumulation of clinical evidence for focal therapy. Because recurring consumables and service revenue builds up as the installed base grows, the pace of sales is crucial. On the other hand, if losses continue, there are concerns about shareholder dilution from additional capital increases, and high dependence on a single product means greater stock price volatility if sales slow.

🎯 Key Growth Drivers
Expansion of the Focal One installed base and growth in recurring revenue
Wider insurance reimbursement for prostate focal therapy
Broader adoption by urologists as clinical evidence accumulates

⚔️ EDAP TMS Core Strengths and Risks

Its patented robotic focused ultrasound technology and recurring revenue structure are strengths, while dependence on a single product and the funding burden from losses are the key risks.

💪 Core Strengths

Patent-based treatment platform
Patents on robotic high-intensity focused ultrasound devices and long clinical experience act as barriers to entry.
Recurring revenue structure
Consumables and service revenue is generated with every procedure on installed devices, building up the revenue base.
Improved business focus
By winding down low-growth segments as discontinued operations, it concentrates management resources on its growth pillar.

⚠️ Key Risks

Single-product dependence
After the restructuring, revenue is concentrated in one product, Focal One, so a sales slowdown would have a large impact.
Losses and capital increase burden
If losses continue, additional capital increases could dilute existing shareholders.
Reimbursement variable
Changes in insurance reimbursement policy for focal therapy determine how quickly hospitals adopt the device.
Currency exposure
As a France-based company, fluctuations in the euro-dollar exchange rate affect its results.

🔄 EDAP TMS Competitors and Related Stocks (Beneficiaries)

A direct competitor in the same minimally invasive urology treatment device space is PRCT, which supplies robotic surgical devices for benign prostatic hyperplasia. Related stocks include ISRG, a surgical robot platform, and BSX, a large medical device group with a broad urology treatment device portfolio. They are grouped together here, and they also act as adjacent threats in the prostate treatment market.

✅ EDAP TMS Investor Checkpoints

Here are the points to review when investing in EDAP TMS. Since earnings have narrowed to the single pillar of Focal One after the restructuring, the pace of device sales, growth in the installed base, and the funding situation during the loss period are the key variables to watch.

CheckpointWhat to CheckCurrent Status
📈 Device salesQuarterly Focal One unit sales and installed base trendRising
💵 Financial healthCash burn rate and likelihood of a capital increaseNeeds monitoring
🏥 ReimbursementChanges in US focal therapy reimbursement policyImprovement expected
🔄 RestructuringProgress in winding down discontinued operationsIn progress

Revenue is concentrated in a single product, so a sales slowdown is immediately reflected in earnings. If losses continue, capital increases could dilute shareholders, and reimbursement policy and euro-dollar exchange rate fluctuations are also sources of earnings volatility. As a micro-cap with low trading volume, its stock price can swing widely.

EDAP TMS is a micro-cap medical device company that has wound down lithotripsy and distribution to concentrate on a single pillar of robotic focused ultrasound. Expansion of the installed base is the key to growth, and given the risks of losses and dilution, staged buying and verification of earnings are advisable.

Briefs · earnings · signals, first Subscribe
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →